Creative Planning
INDV icon

Creative Planning’s Indivior Pharmaceuticals INDV Stock Holding History

Creative Planning’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,610
Closed -$273K – 4153
2025
Q4 		$273K Buy
+7,610
New +$232K ﹤0.01% 3313

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Creative Planning's INDV Position: Q1 2026 in Review

Creative Planning sold out of Indivior Pharmaceuticals (INDV) in Q1 2026, closing a stake of 7,610 shares — an estimated $273K sold.

Creative Planning first reported a position in INDV in Q4 2025 and held it in 1 quarter. The position peaked at $273K in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Creative Planning reported no remaining Indivior Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Creative Planning sold 7,610 Indivior Pharmaceuticals shares in Q1 2026, an estimated $273K.
  • Creative Planning first reported a position in Indivior Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Creative Planning's Indivior Pharmaceuticals position peaked at $273K in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.